Optimizing Polycythemia Vera Management Through a Collaborative Care Model Between Leukemia Oncologists and an...

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacy

Background:

• Polycythemia vera (PV) is a chronic myeloproliferative neoplasm requiring long-term management.
• Current treatment adherence and symptom monitoring are inconsistent, impacting patient outcomes.
• Optimizing care delivery for PV patients is crucial, especially in non-academic settings.

Purpose of the Study:

• To implement and evaluate a pharmacist-led clinical support program for Polycythemia vera (PV) patients.
• To standardize PV care by improving hematocrit (Hct) control and symptom assessment.
• To assess the impact of a specialty pharmacy service (SPS) on PV management.

Main Methods:

• A pharmacist-led program was established at a regional cancer center in collaboration with an integrated specialty pharmacy service.
• Patients with PV and Hct ≥ 45% were identified via diagnosis code screening.
• The SPS pharmacist team provided clinical reviews, pharmacotherapy recommendations, financial support, and patient education.

Main Results:

• The program demonstrated improved identification of opportunities for PV treatment optimization.
• Sustained provider engagement was observed throughout the implementation.
• The model facilitated better hematocrit control and symptom burden assessment.

Conclusions:

• Pharmacist-led interventions can significantly improve the management of Polycythemia vera.
• This model highlights the value of advanced practitioners in optimizing PV care and patient quality of life.
• Standardized care delivery through specialty pharmacy services enhances therapeutic goal achievement.